Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 15 jul 2015 - 07:40

Statutaire naam Galapagos NV

Titel Galapagos licenses Organoid Technology from the HUB foundation for use in cystic fibrosis and IBD research

Bericht Mechelen, Belgium; 15 July 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for pre-clinical research in cystic fibrosis (CF) and inflammatory bowel disease (IBD). Organoids are mini-organs grown in cell culture from biopsies taken from patients; these mini-organs faithfully recapitulate the genetic and phenotypic characteristics of diseased tissues. Organoids have proven to be valuable disease models for the high-throughput screening and validation of innovative medicines, bypassing limitations associated with cell-line and xenograft-based pre-clinical drug studies.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201507150000000005_Galapagos licenseert organoid technologie van de HUB stichting voor taaislijmziekte.pdf (opens in a new window)

201507150000000005_Galapagos licenses Organoid Technology from the HUB foundation for use in cystic fibrosis and IBD research.pdf (opens in a new window)

Datum laatste update: 12 januari 2026